September 3, 2020
UK-based data capture software company, uMotif, has raised £5 million in a Series A investment round led by existing investor AlbionVC.
The funding will accelerate uMotif’s growth and enable further development of its patient-centric and decentralised approach to clinical studies and enable expansion into new study types and more high-demand territories.
WHY IT MATTERS
Life sciences companies...
September 2, 2020
Abbott announced yesterday that its recently cleared FreeStyle Libre 2 integrated continuous glucose monitoring (CGM) system is now covered by the Centers for Medicare and Medicaid Services (CMS), and available to Medicare beneficiaries with diabetes who meet eligibility criteria.
Indicated for diabetes management in patients aged four years or older, the updated version of Abbott's system can...
September 1, 2020
Nurx, a women’s health platform best known for using telemedicine to connect patients with contraceptives and STI testing, is dipping into the migraine space. Today it launched a new service that lets patients virtually connect with a provider and develop an individualized migraine management plan.
Patients pay a $60 annual fee, which includes online medical consultations, a video exam where...
September 1, 2020
Apple and Google are refining their COVID-19 contact tracing framework to fast-track enrollment and, for Apple device owners, completely forego the need to download a separate app, representatives of the companies announced today.
Launched today on iPhones with the iOS 13.7 update, "Exposure Notifications Express" sends device owners in participating states a push notification with the option to...
August 31, 2020
Hogwash, or a brain activity breakthrough? Friday evening came with a long-awaited look at the work of Neuralink, Elon Musk's ambitious brain-computer interface implant startup. In the streamed progress update, Musk ran down a PowerPoint overview of the technology's capabilities, which he likened to "a Fitbit in your skull." The coin-shaped implant will read and wirelessly transmit brain signals...
Credit: Askham Rehabilitation Centre
August 28, 2020
UK rehabilitation centre offers robotics equipment for patients
A UK-based care and rehab centre is now able to deliver robotics expertise as part of its global rehabilitation offering.
Askham Village Community, based in Cambridgeshire, England, is now bringing all its rehab services together with the launch of Askham Rehab, a specialist global rehabilitation service incorporating robotics and...
A product image of the existing AncestryHealth offering.
August 24, 2020
Consumer genomics company Ancestry recently received two FDA 510(k)s – one for an in vitro molecular test that detects genomic variants tied to potential disease risk, and another for a saliva-based DNA specimen-collection kit.
Both of these submissions were received by the FDA in October of last year, which officially cleared them on August 13, according to the agency's 510(k) database.
August 20, 2020
Update: This story has been updated with additional information from Carré Technologies.
OMSignal, a Canadian digital health startup that helped to pioneer the smart clothing space, is out of business as of February 2019, MobiHealthNews has learned. The company declared bankruptcy and sold some of its patents to Honeywell Safety Products.
According to a notice published by PricewaterhouseCoopers...
August 19, 2020
The United States Postal Service has been at the heart of a bitter partisan divide over the last few months of COVID-19 and the U.S. election season.
Prominent Democratic politicians have alleged that recent reforms and administrative changes ushered by recently appointed Postmaster General Louis DeJoy have led to widespread service delays across the country. At the same time, President Donald...
August 18, 2020
23andMe announced this morning that it has received a 510(k) clearance from the FDA that allows its direct-to-consumer personal pharmacogenetics report to guide use of two treatments without the need for confirmatory testing.
This action updates a De Novo approval granted to the consumer genomics company in late 2018. That decision allowed 23andMe to market a test for one of 33...